Evicenter
MarkdownMedical informationP&T meetings
Aqneursa (levacetylleucine)

Ataxia-telangiectasia

Also known as IB1001
Manufacturer
IntraBio
Last updated
209 sources

Section 3 of 6

Product information and disease description

408 evidence topics · 183 sources

Product description

Phase of product development

Summary: development and regulatory status as of October 2026

The FDA approved a supplemental new drug application (NDA 219132, supplement 2) for levacetylleucine (Aqneursa) for oral suspension on 18 September 2026 for the treatment of ataxia in adults and pediatric patients with ataxia-telangiectasia (A-T) weighing at least 15 kg. The approval was granted to IntraBio Inc., and the FDA describes Aqneursa as the first treatment approved for ataxia in patients with A-T. The supplement was dated and received on 19 March 2026. IntraBio announced in May 2026 that the FDA had accepted it with priority review and a PDUFA target action date of 19 September 2026. Levacetylleucine has held orphan drug designation for A-T since 2 October 2018, and the FDA orphan drug record lists the exclusivity end date for the A-T approval as "TBD". Efficacy was evaluated in one randomized, double-blind, placebo-controlled, two-period crossover study of 73 participants (Trial 2, NCT06673056). IntraBio stated in its approval announcement that the product was commercially available. Levacetylleucine was first approved on 24 September 2024 for neurological manifestations of Niemann-Pick disease type C (NPC) with priority review, fast track, orphan drug, and rare pediatric disease designations, and a rare pediatric disease priority review voucher was granted with that approval. The Orange Book lists new chemical entity exclusivity through 24 September 2029, orphan drug exclusivity for the NPC indication through 24 September 2031, and four patents expiring 19 April 2037, one of which (patent 12144792, use code U-4603, submitted 23 September 2026) carries a use code for A-T. In the European Union, Aqneursa was authorised for NPC on 19 January 2026. IntraBio announced a variation application for A-T in June 2026, and the draft agenda of the CHMP meeting of 14 to 17 September 2026 lists the extension of indication for adoption. Acetylleucine has held European Union orphan designation for A-T since 11 January 2019.

FDA approval on 18 September 2026
Special FDA designations: orphan drug designation for A-T
FieldQuoted record
Generic name“levacetylleucine”
Trade name“Aqneursa”
Date designated“10/02/2018”
Orphan designation“Treatment of Ataxia Telangiectasia”
Orphan designation status“Designated/Approved”
Sponsor“IntraBio Inc.”
Marketing approval date“09/18/2026”
Exclusivity end date“TBD”
Exclusivity listed in the Orange Book

Product information

Generic, brand name and therapeutic class of product
Dosage forms and strengths
Material safety data sheet

No evidence found.

Average sales price and wholesale acquisition cost
Summary: estimated monthly and annual cost
  • Price basis: wholesale acquisition cost (WAC) of $14,526 per carton of 28 one-gram packets on 1 January 2026, as reported by IntraBio to the Texas Department of State Health Services, which is $518.79 per packet ($14,526 ÷ 28). The A-T indication uses the 1 gram packet marketed for Niemann-Pick disease type C since 2024, whose WAC was $13,450 per carton at introduction on 24 September 2024 and $13,450 on 1 January 2025; the January 2026 price is 8.0% higher. The New York State Medicaid maximum reimbursable amount of $555.71428 per packet ($15,560 per carton of 28) is 7.1% above the January 2026 WAC, and no state filing or company statement identified gives a WAC after 1 January 2026.
  • Dosing basis: dosage by actual body weight in 1 gram packets per the prescribing information, 2 grams per day (1 gram morning and evening) at 15 kg to less than 25 kg, 3 grams per day (1 gram morning, afternoon, and evening) at 25 kg to less than 35 kg, and 4 grams per day (2 grams morning, 1 gram afternoon, 1 gram evening) at 35 kg or more. Each dose is one or two whole packets, so cost is calculated per packet used.
  • Base case: 4 grams per day at 35 kg or more, the weight band of 38 of 73 participants (52%) in the pivotal trial. $518.79 per packet × 4 packets per day × 365 days = $757,427 per year; ÷ 12 = $63,119 per month.
  • Range: $378,714 per year ($31,559 per month) at 2 grams per day, $568,070 per year ($47,339 per month) at 3 grams per day, and $757,427 per year ($63,119 per month) at 4 grams per day. At the New York Medicaid amount per packet, the 4 grams per day cost is $811,343 per year ($67,612 per month).
  • Rationale for the range: the label sets the daily dose by three body weight bands, and 18 of 73 trial participants (25%) weighed 15 kg to less than 25 kg and 17 (23%) weighed 25 kg to less than 35 kg; the label gives no dose reduction, titration, or renal or hepatic adjustment, and the price is the same per gram at every dose because one packet strength is marketed.
  • Scope: drug acquisition cost at list price, excluding administration, dispensing, markups, rebates, and patient cost sharing.
Wholesale acquisition cost at U.S. introduction: manufacturer filing with the California Department of Health Care Access and Information
FieldQuoted record
Manufacturer name“Intrabio Inc.”
National drug code“83853010101”
Drug product description“Aqneursa (levacetylleucine) 1 gram sachet, carton of 28”
Date introduced to market“2024-09-24”
Wholesale acquisition cost at introduction (USD)“13450.0000”
Wholesale acquisition cost on 1 January 2025: manufacturer report to the Texas Department of State Health Services
FieldQuoted record
Manufacturer name“IntraBio Inc.”
Drug trade name“Aqneursa”
National drug code“83853010101”
Wholesale acquisition cost on 1 January 2025 (USD)“13450”
Estimated wholesale acquisition cost per 28 days: pharmacy benefit manager summary, fourth quarter 2024
ProductEstimated wholesale acquisition cost (WAC)
Aqneursa (levacetylleucine)“$40K per 28 days”
Federal Supply Schedule and Big Four prices per carton of 28 packets
New York Medicaid maximum reimbursable amount per packet: list effective 29 September 2026
FieldQuoted record
Description“AQNEURSA 1 GRAM GRANULE PACKET”
National drug code“83853-0101-01”
Maximum reimbursable amount cost“555.7142800”
Basis of maximum reimbursable amount“EA”
Effective date“09/29/2026”
Maximum quantity“112.000”
Wholesale acquisition cost announced with the ataxia-telangiectasia approval

No evidence found.

Annual cost by body weight band

No evidence found.

National Average Drug Acquisition Cost

No evidence found.

Average sales price

Not applicable.

American hospital formulary service (AHFS), or other drug classification
ATC classification: WHO index
ATC classification: European Medicines Agency record
FieldQuoted record
Anatomical therapeutic chemical (ATC) code“N07XX27”
Pharmacotherapeutic group“Other nervous system drugs”
Indication
Pharmacology
Mechanism of action
Mechanism as described by the European regulator
Cellular uptake: acetylation switches transport from LAT1 to MCT1 and organic anion transporters
Pharmacodynamics
Pharmacokinetics
Contraindications/Warnings/Precautions/Adverse effects
Warnings and precautions
Adverse reactions in A-T at an incidence of 5% or more in Treatment Period I of Trial 2
Adverse reactionAQNEURSA, N=36, n (%)Placebo, N=37, n (%)
Fall“2 (6)”“1 (3)”
Skin laceration“2 (6)”“0 (0)”
Urinary tract infection“2 (6)”“1(3)”
Adverse reactions in NPC at an incidence of 5% or more in Treatment Period I of Trial 1
Adverse reactionAQNEURSA, N=30, n (%)Placebo, N=30, n (%)
Upper respiratory tract infection“5 (17)”“1 (3)”
Abdominal pain“2 (7)”“0 (0)”
Dysphagia“2 (7)”“0 (0)”
Vomiting“2 (7)”“0 (0)”
Special populations
Drug/Drug, drug/disease interactions
Effects of other drugs on levacetylleucine
Effects of levacetylleucine on other drugs
Dosing and administration
Dosage
Recommended dosage by body weight
Body weightMorning doseAfternoon doseEvening dose
15 kg to less than 25 kg“1 gram”“No Dose”“1 gram”
25 kg to less than 35 kg“1 gram”“1 gram”“1 gram”
35 kg or more“2 grams”“1 gram”“1 gram”
Administration
Access and distribution
Published payer policies that predate the A-T approval: Medical Mutual
Published payer policies that predate the A-T approval: UnitedHealthcare
Payer coverage policies with criteria for the A-T indication

No evidence found.

Co-prescribed/Concomitant therapies
Effect of levacetylleucine on quality measures

No evidence found.

Product comparison
Summary: levacetylleucine, intra-erythrocyte dexamethasone, and the racemate
  • Levacetylleucine is supplied as an oral suspension in 1 gram packets and is given two or three times daily according to body weight. In Trial 2 of the prescribing information, 73 participants with A-T received levacetylleucine and placebo for 12 weeks each in a crossover design, and the least squares treatment effect on the functional SARA total score was -0.6 (95% CI -0.9 to -0.2). The FDA announcement describes Aqneursa as the first treatment approved for ataxia in A-T.
  • Intra-erythrocyte dexamethasone sodium phosphate (eDSP, formerly EryDex) is given by intravenous infusion: once a month for 6 months in ATTeST, and six infusions every 21 to 30 days in NEAT. In ATTeST, 175 participants received treatment and the least squares mean differences from placebo in mICARS change were -1.37 for the low-dose group and -1.40 for the high-dose group; the primary endpoint was not met. NEAT randomized 105 participants, its primary endpoint did not reach statistical significance (p=0.0851), and the sponsor announced that it would cease clinical development of eDSP.
  • N-acetyl-DL-leucine, the racemate marketed in France as Tanganil for acute vertigo, has been reported in A-T in a case series of 6 participants and in a single case report. In the ALCAT crossover trial of 108 participants with cerebellar ataxia of hereditary, nonhereditary, or unknown type, the mean treatment difference in SARA total score between the racemate and placebo was 0.23 points (95% CI -0.40 to 0.85).
  • No head-to-head clinical comparison of levacetylleucine with the racemate has been performed. The CHMP concluded that the data submitted for the European application did not allow the conclusion that the two differ significantly in efficacy or safety.
Intra-erythrocyte dexamethasone sodium phosphate: ATTeST phase 3 trial
AttributePublished abstract
Design“This multicentre, randomised, double-blind, placebo-controlled, phase 3 trial was done at 22 centres in 12 countries (Australia, Belgium, Germany, India, Israel, Italy, Norway, Poland, Spain, Tunisia, the UK, and the USA).”View highlighted excerpt for this quote
Population“Eligible participants were children aged 6 years or older weighing more than 15 kg who met clinical criteria for ataxia telangiectasia but who had preserved autonomous gait.”View highlighted excerpt for this quote
Regimen“Intravenous intra-erythrocyte dexamethasone sodium phosphate was administered once a month for 6 months.”View highlighted excerpt for this quote
Participants treated“175 patients received at least one dose of treatment (59 patients received the low dose and 57 received the high dose of intra-erythrocyte dexamethasone sodium phosphate, and 59 received placebo).”View highlighted excerpt for this quote
Primary endpoint“Compared with the placebo group, no differences were identified with regard to change in mICARS score from baseline to 6 months in the low-dose group (least squares mean difference -1·37 [95% CI -2·932 to 0·190]) or the high-dose group (-1·40 [-2·957 to 0·152]; p=0·0765).”View highlighted excerpt for this quote
Serious adverse events“Serious adverse events were observed in six (10%) of 59 participants in the low-dose group, seven (12%) of 57 participants in the high-dose group, and seven (12%) of 59 participants in the placebo group.”View highlighted excerpt for this quote
Corticosteroid adverse effects“There were no reports of hyperglycaemia, hypertension, hirsutism, or Cushingoid appearance in any of the treatment groups, nor any treatment-related deaths.”View highlighted excerpt for this quote
Interpretation“Although there were no safety concerns, the primary efficacy endpoint was not met, possibly related to delays in treatment reducing the number of participants who received treatment as outlined in the protocol, and potentially different treatment effects according to age.”View highlighted excerpt for this quote
Intra-erythrocyte dexamethasone sodium phosphate: NEAT phase 3 trial topline results
Levacetylleucine and the racemate: European regulatory appraisal

“Of note, it should be kept in mind that insufficient evidence was provided in non-clinical studies that levacetylleucine is superior to the racemic NADLL, which is approved as Tanganil in France.” (opens the source at this quote in a new tab)

“A direct head-to-head comparison between NALL (N-acetyl-L-leucine, L-enantiomer) and the racemate, NADLL (N-acetyl-DL-leucine), to compare their efficacy and safety profiles has not been performed in patients with Niemann-Pick disease type C or any other similar indication, due to feasibility/ethical issues, which are acknowledged.” (opens the source at this quote in a new tab)

“Although PK studies demonstrated that administration of NADL as part of the racemate supresses exposure to NALL, pharmacological data do not suggest that efficacy of the racemate is reduced because of this.” (opens the source at this quote in a new tab)

“Formulations: powder for oral suspension (NALL) versus tablets (NADLL), which can influence PK and bioavailability and therefore pharmacological activity.” (opens the source at this quote in a new tab)

“In conclusion, on the basis of the totality of clinical data provided by the Applicant in this re-examination procedure, it is not possible to conclude that levacetylleucine (N-acetyl-L-leucine) differs significantly in properties with regard to safety and/or efficacy from N-acetyl-DL-leucine.” (opens the source at this quote in a new tab)

Place of product in therapy

Disease description

Definition and etiology
Genotype and residual ATM kinase activity
Epidemiology
Incidence of Ataxia-telangiectasia
United States birth incidence: nationwide case finding
MeasureEstimate
Cases identified in 1970 to 1972 and 1980 to 1984“231 white, 29 black, and three Oriental A-T cases”View highlighted excerpt for this quote
Birth rate of identified white patients, 1965 to 1969“3.0 per million live births”View highlighted excerpt for this quote
Highest observed state incidence (Michigan, 1965 to 1969)“11.3 per million births”View highlighted excerpt for this quote
Prevalence of Ataxia-telangiectasia
Founder populations with higher carrier frequency
PopulationHeterozygote frequency
Druze population in northern Israel“One in three to one in 15”
Moroccan and Tunisian Jewish population“One in 81”
Romani population in Spain“One in 36”
Natural history, survival, and mortality
Mean age by walking capacity category: Global A-T Family Data Platform
Structure of SARA and its limitations in A-T

“It assesses 8 domains: gait, stance, sitting ability, speech disturbance, finger chase, nose-finger test, fast alternating hand movements and heel-shin slide. It carries a maximum score of 40 with higher scores indicating more severe ataxia symptoms” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“However, the SARA score remains unvalidated specifically for use in A-T and is not without its limitations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Many classical A-T patients lose ambulation by their teenage years, and it is unclear how this influences the assessment of disease progression in non-ambulant patients who continue to report clinical deterioration” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The medical records of 55 individuals (males = 27, females = 28) with genetically confirmed diagnoses of A-T who attended the National Adult A-T Clinic at Royal Papworth Hospital over a 7-year period were retrospectively reviewed in a longitudinal manner.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The A-T NEST correlates strongly with the SARA score at the single timepoint level and changes proportionally with the SARA score longitudinally which demonstrates its ability to track the severity of the disease over time.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Pathophysiology
Cerebellar degeneration and Purkinje cell loss
Diagnosis
Yield of molecular genetic testing of ATM
MethodProportion of pathogenic variants identified
Sequence analysis“90%-95%”
Deletion/duplication analysis“5%-10%”
Serum alpha-fetoprotein
Newborn screening by T-cell receptor excision circles: proportion of classic A-T detected
Clinical presentation - signs and symptoms
Immunological symptoms: immunodeficiency and infections
Long-term morbidity
Burden of Ataxia-telangiectasia
Humanistic burden and health-related quality of life
PedsQL study in children and young people: total scores compared with healthy controls
RaterAtaxia-telangiectasiaHealthy controlsp value
Child or young person, total QoL“53.8 ± 12.6”“81.8 ± 11.8”“<.0005”
Parent proxy, total QoL“43.2 ± 13.2”“90.7 ± 8.7”“<.0005”
Economic burden and healthcare resource utilization
Cost-of-illness and claims-based studies specific to ataxia-telangiectasia

No evidence found.

Cost of illness of inherited ataxia in Ireland: a cohort that included 4 participants with ataxia-telangiectasia
Economic impact of Ataxia-telangiectasia on families
Economic impact of diagnostic testing
Cost of diagnostic testing specific to ataxia-telangiectasia

No evidence found.

Approaches to treatment

Current treatment options and standard of care
Multidisciplinary supportive care
Physical, occupational, and speech therapy
Symptomatic medications for ataxia and movement disorders
Corticosteroids
Immunoglobulin replacement and infection prophylaxis
Respiratory care
Nutritional support and gastrostomy
Limitations of current therapies
Summary

Before the approval of levacetylleucine in September 2026, no therapy was approved for ataxia-telangiectasia in any market, and no treatment was known to slow or stop the neurological decline. Published guidance rests on expert opinion and small non-randomized studies: the European Respiratory Society statement reports no randomized controlled trials of respiratory treatments and no placebo-controlled trials of prophylactic antibiotics or immunoglobulin replacement, and the United Kingdom guidance for children states that it is not an evidence-based guideline. Evidence for symptomatic drugs comes from open-label studies of amantadine (17 participants, 8 weeks), 4-aminopyridine (4 participants), and nicotinamide riboside (24 participants, 4 months). Oral betamethasone reduced the ICARS total score by a median of 13 points in a crossover trial of 13 participants; in a two-year study of 6 participants, the neurological scores of 4 participants deteriorated and all 6 had transient adrenal dysfunction. Intra-erythrocyte dexamethasone did not meet its primary endpoint in the ATTeST trial (175 participants treated) or in the NEAT trial (105 participants), and its sponsor ceased clinical development in January 2026. A 2026 systematic review of 13 studies with 314 participants concluded that no intervention had demonstrated sustained efficacy in adequately powered controlled trials. Physical, occupational, and speech therapies may maintain function and do not slow neurodegeneration.

Place in treatment, anticipated use, and care setting
Summary

Levacetylleucine was approved in the United States in September 2026 for ataxia in adults and pediatric patients with ataxia-telangiectasia weighing at least 15 kg, and the FDA describes it as the first treatment approved for ataxia in this disease. The indication is defined by diagnosis and body weight, and the label lists no contraindications. The pivotal trial enrolled 73 participants aged 4 years or older with genetically confirmed disease and a SARA score of 7 to 34; participants younger than 4 years, asymptomatic participants, and participants with advanced disease who could not complete functional assessments were excluded. The trial authors propose levacetylleucine as a first-line, foundational therapy. Dosing follows body weight (2 g, 3 g, or 4 g per day in two or three doses) as an oral suspension taken with or without food or given through a gastrostomy tube, and the label directs patients and caregivers to the Instructions for Use. The approved indication covers ataxia; published guidance continues to recommend multidisciplinary supportive care for immunodeficiency, respiratory disease, nutrition, and malignancy surveillance. Pregnancy status is verified before initiation in females of reproductive potential, and concomitant N-acetyl-DL-leucine and N-acetyl-D-leucine are avoided. The 12-week controlled period measured a symptomatic effect that was lost during the subsequent placebo period, and long-term data depend on the ongoing open-label extension. The manufacturer stated that the product was commercially available at approval.

Heterogeneity of treatment effect
Predefined subgroup analyses of the primary endpoint in IB1001-303
Size of the age, age-at-diagnosis, and dose subgroups in IB1001-303
SubgroupParticipants (n=73)
Paediatric (<18 years)“47 (64%)”View highlighted excerpt for this quote
Adult (≥18 years)“26 (36%)”View highlighted excerpt for this quote
Age at diagnosis: early-infantile (<2 years)“51 (70%)”View highlighted excerpt for this quote
Age at diagnosis: late-infantile (2 to <6 years)“16 (22%)”View highlighted excerpt for this quote
Age at diagnosis: juvenile (6 to <15 years)“3 (4%)”View highlighted excerpt for this quote
Age at diagnosis: adolescent or adult (≥15 years)“3 (4%)”View highlighted excerpt for this quote
Weight 15 to <25 kg (2 g per day)“18 (25%)”View highlighted excerpt for this quote
Weight 25 to <35 kg (3 g per day)“17 (23%)”View highlighted excerpt for this quote
Weight ≥35 kg (4 g per day)“38 (52%)”View highlighted excerpt for this quote
Classic versus variant ataxia-telangiectasia

No evidence found.

Care management intervention strategies
Other product development or post-marketing obligations required by the FDA
Summary: postmarketing obligations for levacetylleucine

The FDA approval letter for the A-T supplement (NDA 219132/S-002, 18 September 2026) lists no postmarketing requirement or postmarketing commitment and contains no pediatric assessment section. It requires submission of structured product labeling within 14 days, patent information within 30 days, and compliance with the reporting requirements for an approved NDA. The original approval letter of 24 September 2024 for the NPC indication set eight postmarketing requirements under section 505(o) (PMR 4683-1 to 4683-8), comprising seven nonclinical toxicology and carcinogenicity studies and one clinical drug-drug interaction trial with a P-gp probe substrate, and one postmarketing commitment (PMC 4683-9), a food effect trial. The agreed final report dates run from December 2024 to June 2029. That letter states that the application was exempt from the Pediatric Research Equity Act assessment requirement because the product has orphan drug designation for the indication. The prescribing information revised in September 2026 states that animal studies of carcinogenic potential and of fertility have not been conducted.

Postmarketing commitment from the 2024 approval: food effect trial
Ongoing post-approval monitoring
Product registry for ataxia-telangiectasia

No evidence found.

Expected outcomes of therapy
Minimal clinically important difference established in ataxia-telangiectasia

No evidence found.